Key Drugs in the ActRII Pathway - Targeting INHBE and ALK7

The discovery of INHBE and ALK7 as potential drug targets has opened up new avenues in the development of therapies for obesity and metabolic disorders. This article explores the key drugs targeting INHBE and ALK7, their mechanisms, development status, and potential impact on the treatment landscape.

Using the Patsnap Synapse for advanced target searches with INHBE and ALK7, a set of drugs in different development stages were identified. These include drugs in Phase I, those with an Investigational New Drug (IND) application, and others in preclinical development.

Arrowhead and Alnylam, well - known foreign small nucleic acid biotech companies, have established siRNA pipelines targeting INHBE and ALK7. For example, Arrowhead plans to advance two RNAi - based candidates, ARO - INHBE and ARO - ALK7, into clinical stages for the treatment of obesity and metabolic disorders. In China, Suzhou Silence and Bridge Biopharma have also entered this research domain. These siRNA drugs work by interfering with the gene expression of INHBE or ALK7, potentially modulating the related signaling pathways involved in metabolism and body weight regulation. Compared to current weight - loss drugs, they are expected to offer better outcomes in reducing muscle loss during the weight - loss process.

The development of drugs targeting INHBE and ALK7 represents a promising area of research. Although currently in early development stages, these drugs have the potential to revolutionize the treatment of obesity and metabolic disorders. Continuous monitoring of their progress, especially the siRNA drug patents in the Synapse database, is essential for keeping abreast of the latest advancements in this field.

For more information, please click the image link below to access the full report.